What is a stock summary page? Click here for an overview.
Business Description
Castle Biosciences Inc
NAICS : 621511
SIC : 8071
ISIN : US14843C1053
Description
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.13 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.74 | |||||
| Interest Coverage | 15.03 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.5 | |||||
| Beneish M-Score | -2.59 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 44.7 | |||||
| 3-Year Book Growth Rate | -0.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.52 | |||||
| 9-Day RSI | 40.19 | |||||
| 14-Day RSI | 38.11 | |||||
| 3-1 Month Momentum % | -5.78 | |||||
| 6-1 Month Momentum % | -9.26 | |||||
| 12-1 Month Momentum % | 18.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.29 | |||||
| Quick Ratio | 7.13 | |||||
| Cash Ratio | 5.93 | |||||
| Days Inventory | 46.45 | |||||
| Days Sales Outstanding | 50.22 | |||||
| Days Payable | 51.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -2.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.87 | |||||
| Operating Margin % | 2.61 | |||||
| Net Margin % | 5.49 | |||||
| FCF Margin % | 11 | |||||
| ROE % | 4.31 | |||||
| ROA % | 3.73 | |||||
| ROIC % | 3.48 | |||||
| 3-Year ROIIC % | 40.17 | |||||
| ROC (Joel Greenblatt) % | 31.8 | |||||
| ROCE % | 4.96 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 32.42 | |||||
| PE Ratio without NRI | 32.42 | |||||
| Price-to-Owner-Earnings | 47.63 | |||||
| PS Ratio | 1.76 | |||||
| PB Ratio | 1.26 | |||||
| Price-to-Tangible-Book | 1.64 | |||||
| Price-to-Free-Cash-Flow | 16.76 | |||||
| Price-to-Operating-Cash-Flow | 9.22 | |||||
| EV-to-EBIT | 13.81 | |||||
| EV-to-Forward-EBIT | -5.15 | |||||
| EV-to-EBITDA | 8.59 | |||||
| EV-to-Revenue | 0.92 | |||||
| EV-to-Forward-Revenue | 1.06 | |||||
| EV-to-FCF | 8.37 | |||||
| Price-to-GF-Value | 0.61 | |||||
| Price-to-Projected-FCF | 2.37 | |||||
| Price-to-Graham-Number | 1.54 | |||||
| Price-to-Net-Current-Asset-Value | 2.01 | |||||
| Price-to-Net-Cash | 2.63 | |||||
| Earnings Yield (Greenblatt) % | 7.24 | |||||
| FCF Yield % | 6.38 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CSTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Castle Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 332.069 | ||
| EPS (TTM) ($) | 0.62 | ||
| Beta | 1.24 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 53.36 | ||
| 14-Day RSI | 38.11 | ||
| 14-Day ATR ($) | 1.078479 | ||
| 20-Day SMA ($) | 20.355 | ||
| 12-1 Month Momentum % | 18.8 | ||
| 52-Week Range ($) | 16.965 - 35.84 | ||
| Shares Outstanding (Mil) | 28.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Castle Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Castle Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Castle Biosciences Inc Frequently Asked Questions
What is Castle Biosciences Inc(CSTL)'s stock price today?
The current price of CSTL is $20.10. The 52 week high of CSTL is $35.84 and 52 week low is $16.97.
When is next earnings date of Castle Biosciences Inc(CSTL)?
The next earnings date of Castle Biosciences Inc(CSTL) is 2025-05-02 Est..
Does Castle Biosciences Inc(CSTL) pay dividends? If so, how much?
Castle Biosciences Inc(CSTL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers